Skip to main content

Table 3 Health state utility weights

From: Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers

Screening and diagnostics

 

95% CI

 MRI screening*

1.000

-

 Mammography

1.000

-

 Diagnostic workup

0.987

0.761-1.00

Treatment†

 In situ

0.965

0.463-1.00

 Localized

0.860

0.330-1.00

 Regional

0.675

0.315-0.929

 Distant

0.380

0.211-0.564

 Progression (end of life)

0.380

0.211-0.564

 Remission

0.965

0.463-1.00

Dead

0.000

-

Well

1.000

-

  1. Abbreviations: CI Confidence interval.
  2. * Full utility (1.00) assumed for screening states and ‘Well’ state; not varied in probabilistic sensitivity analysis.
  3. † Treatment utilities by stage at diagnosis applied for 18 months, after which ‘Remission’ value applied until progression and death or transition to ‘Well,’ 10-yrs post-diagnosis; utilities for localized, regional, distant disease, and disease progression states were derived from Schleinitz et al.[38], and utility for diagnostic work-up, remission and in situ disease were from Bonomi et al.[39].